<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129648</url>
  </required_header>
  <id_info>
    <org_study_id>BCX4208-202</org_study_id>
    <nct_id>NCT01129648</nct_id>
  </id_info>
  <brief_title>Study to Evaluate sUA-Lowering Activity, Safety &amp; PK Interaction of Oral BCX4208 &amp; Allopurinol Admin. in Subjects w/Gout</brief_title>
  <official_title>A Randomized, Double-Blind, Multi-center, Placebo-Controlled, Combination Study to Evaluate the Urate-Lowering Activity, Safety, and Potential Pharmacokinetic Interaction of Oral BCX4208 and Allopurinol Administered in Subjects With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and efficacy of BCX4208 alone and in combination with allopurinol in&#xD;
      subjects with gout.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 2, randomized, double-blind, multi-center, placebo-controlled study to&#xD;
      evaluate efficacy and safety of BCX4208 alone and in combination with allopurinol in&#xD;
      approximately 80 subjects with gout. The study is a factorial design, evaluating doses of&#xD;
      BCX4208 previously found to be safe and well-tolerated in healthy subjects and subjects with&#xD;
      psoriasis and gout. Doses of allopurinol are according to package insert recommendations.&#xD;
&#xD;
      Approximately 80 subjects will be randomized equally to one of 16 treatment groups.&#xD;
&#xD;
      The study will consist of 3 periods: the Screening Period, the Treatment Period, and the&#xD;
      Follow-Up Period. The Screening period will be conducted within Day -30 to Day -1, as long as&#xD;
      all inclusion and exclusion criteria are satisfied (see Section 8). For subjects receiving&#xD;
      urate-lowering therapy; these subjects must discontinue the urate-lowering therapy by Day -14&#xD;
      to assure a washout period of at least 14 days before entering the Treatment Period. Some&#xD;
      Screening procedures such as a recording of medical history and clinical laboratory tests&#xD;
      performed at Screening only may be performed at any time during the Screening Period (Day -30&#xD;
      to Day -1). Other Screening procedures must be performed within the 7 days prior to the first&#xD;
      dose of study drug (i.e., from Day -7 to Day -1); these include: physical examination,&#xD;
      height, weight, clinical chemistry (including baseline and qualifying sUA), hematology, and&#xD;
      urinalysis evaluations, CD4+, CD8+, CD20+, and CD56+ lymphocyte counts, a serum pregnancy&#xD;
      test in females of child-bearing potential, 12-lead ECG, and vital signs assessments. An&#xD;
      otherwise qualified subject may have up to 2 repeated determinations of sUA and/or lymphocyte&#xD;
      subsets assayed to meet the entry criteria for this study, as long as the qualifying sUA and&#xD;
      lymphocyte subsets assays occur 7 or fewer days prior to the first dose of study drug. These&#xD;
      assessments will constitute the Baseline assessments for the purpose of comparisons with&#xD;
      these same assessments post-dose.&#xD;
&#xD;
      Gout flare prophylaxis with colchicine or naproxen is required to be started prior to the&#xD;
      first dose of study drug. Colchicine 0.6 mg once a day will begin at least 7 days prior to&#xD;
      Day 1, or naproxen 250 mg twice daily will be started at least 48 hours prior to Day 1. For&#xD;
      subjects who discontinue urate-lowering therapy, the required gout flare prophylaxis will&#xD;
      begin at or before the cessation of the urate-lowering therapy.&#xD;
&#xD;
      A recording of concomitant medications and AEs will take place from the time of the signing&#xD;
      of the Informed Consent Form (ICF) and throughout the duration of the study.&#xD;
&#xD;
      The Treatment Period begins on Day 1. Subjects are to arrive at the study clinic on Day 1&#xD;
      after an overnight fast. After a final review of eligibility criteria, pre-dose vital signs&#xD;
      assessments, and BCX4208, allopurinol, and oxypurinol PK blood draw have been performed,&#xD;
      subjects will be randomized and administered the first dose of study drug. Subjects will&#xD;
      remain in the study clinic for Hour 2, Hour 4, and Hour 8 PK sampling and will return to the&#xD;
      study clinic for efficacy and safety evaluations prior to dosing on Days 2, 8, and 15.&#xD;
&#xD;
      Subjects will take study drug daily from Day 1 to Day 21, so that the Day 22 evaluation will&#xD;
      occur approximately 24 hours after the last dose of study drug. After the Day 22 evaluation,&#xD;
      subjects will enter the Follow-Up Period and will return to the study clinic on Day 29 for&#xD;
      safety evaluation. Subjects may resume their prior urate-lowering therapy after the&#xD;
      assessments on Day 29.&#xD;
&#xD;
      Subjects who on Day 29 have unresolved treatment-emergent AEs will be followed beyond Day 29&#xD;
      until either resolution of the AE or until clinically stable. This subset of subjects will&#xD;
      conclude their study participation at the Day 50 Telephone Safety Follow-Up Contact.&#xD;
&#xD;
      Efficacy will be assessed during the study by means of sUA concentrations. Safety will be&#xD;
      assessed during the study by means of physical examination, weight, clinical chemistry,&#xD;
      hematology, and urinalysis parameters, absolute CD4+, CD8+, CD20+, and CD56+ lymphocyte&#xD;
      counts, 12-lead ECG, vital signs assessments, and AE assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the dose response relationship of BCX4208 when administered as a monotherapy and in combination with allopurinol on sUA.</measure>
    <time_frame>Day 22</time_frame>
  </primary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>BCX4208 placebo + Allopurinol placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 placebo + Allopurinol 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 placebo + Allopurinol 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 Placebo + Allopurinol 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 20 mg + Allopurinol Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 20 mg + Allopurinol 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 20 mg + Allopurinol 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 20 mg + Allopurinol 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 40 mg + Allopurinol placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 40 mg + Allopurinol 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 40 mg + Allopurinol 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 40 mg + Allopurinol 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 80 mg + Allopurinol Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 80 mg + Allopurinol 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 80 mg + Allopurinol 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCX4208 80 mg + Allopurinol 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered daily for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered daily for 21 days</description>
    <arm_group_label>BCX4208 placebo + Allopurinol placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 placebo + Allopurinol 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 placebo + Allopurinol 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 Placebo + Allopurinol 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX4208</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 20 mg + Allopurinol Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 20 mg + Allopurinol 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 20 mg + Allopurinol 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 20 mg + Allopurinol 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX4208</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 40 mg + Allopurinol placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 40 mg + Allopurinol 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 40 mg + Allopurinol 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 40 mg + Allopurinol 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX4208</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 80 mg + Allopurinol Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 80 mg + Allopurinol 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 80 mg + Allopurinol 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Administered daily for 21 days.</description>
    <arm_group_label>BCX4208 80 mg + Allopurinol 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX4208</intervention_name>
    <description>Adminstered daily for 21 days</description>
    <arm_group_label>BCX4208 20 mg + Allopurinol 100 mg</arm_group_label>
    <arm_group_label>BCX4208 20 mg + Allopurinol 200 mg</arm_group_label>
    <arm_group_label>BCX4208 20 mg + Allopurinol 300 mg</arm_group_label>
    <arm_group_label>BCX4208 40 mg + Allopurinol 100 mg</arm_group_label>
    <arm_group_label>BCX4208 40 mg + Allopurinol 200 mg</arm_group_label>
    <arm_group_label>BCX4208 40 mg + Allopurinol 300 mg</arm_group_label>
    <arm_group_label>BCX4208 80 mg + Allopurinol 100 mg</arm_group_label>
    <arm_group_label>BCX4208 80 mg + Allopurinol 200 mg</arm_group_label>
    <arm_group_label>BCX4208 80 mg + Allopurinol 300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 to &lt;70 years, with screening sUA &gt; 8.0 mg/dL.&#xD;
&#xD;
          2. Diagnosis of gout according to the criteria of the American Rheumatism Association&#xD;
             (1977).&#xD;
&#xD;
          3. Be willing and able to take colchicine 0.6 mg per day or naproxen 250 mg twice daily&#xD;
             (with proton pump inhibitor if needed) as prophylaxis for gout flares.&#xD;
&#xD;
          4. Be willing to abstain from blood donations from Day -14 to Day 29/Early Termination.&#xD;
&#xD;
          5. Female participants must be sexually abstinent, sterile, post-menopausal, or on stable&#xD;
             contraception.&#xD;
&#xD;
               -  Post-menopausal - females greater ≥ 45 years of age whose last menstrual period,&#xD;
                  including spotting, was &gt; 1 year ago.&#xD;
&#xD;
               -  Stable contraception - now requires a double barrier method, e.g. condom or&#xD;
                  diaphragm with spermicide.&#xD;
&#xD;
          6. Male participants must be abstinent, vasectomized or using condoms with spermicide&#xD;
             with partners meeting female requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to tolerate allopurinol.&#xD;
&#xD;
          2. Gout Flare during Screening Period that is resolved less than 2 weeks prior to first&#xD;
             treatment.&#xD;
&#xD;
          3. Unstable angina, history of symptomatic arrhythmia, or Class III or IV heart failure.&#xD;
&#xD;
          4. ECG Findings: history of congenital long QT syndrome; QTc interval &lt; 350 msec or &gt; 475&#xD;
             msec.&#xD;
&#xD;
          5. Inadequately controlled hypertension (above either or both 150/95 mm Hg).&#xD;
&#xD;
          6. Moderate or severe renal impairment and/or calculated creatinine clearance &lt;60 mL/min&#xD;
             (using Cockcroft-Gault formula).&#xD;
&#xD;
          7. ALT or AST &gt; 2.0 x ULN.&#xD;
&#xD;
          8. CD4+ count by flow cytometry (&lt;500 cells/mm3).&#xD;
&#xD;
          9. Hgb &lt;12 g/dL or &gt; 17 g/dL (males) or &lt; 11 g/dL or &gt; 16 g/dL (females).&#xD;
&#xD;
         10. Hct &lt; 37% or &gt; 51% (males) &lt; 33% or &gt; 47% (females).&#xD;
&#xD;
         11. WBC &lt; 3.7 x 109/L or &gt; 11 x 109/L.&#xD;
&#xD;
         12. Positive Pregnancy Test.&#xD;
&#xD;
         13. Females who are pregnant, breastfeeding or planning a pregnancy with the next 4&#xD;
             months.&#xD;
&#xD;
         14. Positive serology for hepatitis B surface antigen or hepatitis C or HIV type I (HIV&#xD;
             Ab).&#xD;
&#xD;
         15. Immunocompromised or on systemic immunosuppressant medications (including anakinra)&#xD;
             within 14 days of study dosing.&#xD;
&#xD;
         16. Use of azathioprine or 6-mercatopurine within 14 days of study dosing.&#xD;
&#xD;
         17. Use of HCTZ in doses &gt; 50mg per day within 14 days of study dosing.&#xD;
&#xD;
         18. Recipient of any live, attenuated vaccine within 6 weeks of Screening.&#xD;
&#xD;
         19. Receipt of sUA-lowering drugs, ACTH, within 14 days of study dosing.&#xD;
&#xD;
         20. Use of systemic corticosteroids within 4 weeks prior to study dosing.&#xD;
&#xD;
         21. Clinically significant and relevant drug allergies.&#xD;
&#xD;
         22. Chronic or recurrent infections (3 infections at same site) within 12 months.&#xD;
&#xD;
         23. Cancer within 12 months (except nonmelanomatous localized skin cancer.&#xD;
&#xD;
         24. Alcohol or drug abuse.&#xD;
&#xD;
         25. Investigational drug within 30 days of study dosing.&#xD;
&#xD;
         26. Other medical conditions which, in the opinion of the PI, would jeopardize the safety&#xD;
             of the study subject or impact the validity of the study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <zip>38654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>May 21, 2010</study_first_submitted>
  <study_first_submitted_qc>May 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2010</study_first_posted>
  <disposition_first_submitted>January 18, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>January 18, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 23, 2012</disposition_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperuricemia, gout</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

